Abbott (NYSE:ABT) shares were up today after the healthcare company posted second-quarter financial results that topped estimates on Wall Street. For the three months ended June 30, Abbott posted profits of $733 million, or 41¢ per share, on sales of $7.77 billion. The company saw its quarterly profits grow 159% on sales growth of 17% compared […]
abbott
FDA approves Abbott’s latest drug-eluting stent
Abbott (NYSE:ABT) said today that it won FDA approval for its Xience Sierra everolimus-eluting coronary stent. The company’s device features a thin profile, improved flexibility and longer lengths than previous stents. The device and delivery system were designed to help clinicians tackle complex cases, like those involving multiple or totally blocked vessels, according to Abbott. “We […]
For this Abbott executive, solving problems isn’t enough: ‘We need to add value’
As payers and providers across healthcare shift their focus to value-based care, leaders in the medical device industry are racing to keep up. Michael Pederson, SVP of cardiac arrhythmias and heart failure at Abbott, told MassDevice.com why simply solving problems with new technology isn’t enough anymore. What was your path like from electrical engineering to […]
Abbott’s Xience Sierra drug-eluting coronary stent wins reimbursement in Japan
Abbott (NYSE:ABT) said today that it won national reimbursement in Japan for its everolimus-eluting stent, Xience Sierra, which is designed to treat patients with coronary artery disease. The company’s latest drug-eluting device features a thinner profile, increased flexibility and longer lengths than previous stents, according to Abbott. The healthcare firm said it developed Xience Sierra to […]
Medtech stories we missed this week: April 27, 2018
From DuPuy Synthes’s spinal implant launch to Lumendi’s FDA clearance, here are seven medtech stories we missed this week but thought were still worth mentioning. 1. DePuy Synthes launches spinal implants DePuy Synthes announced in an April 26 press release that it has launched its Proti 360º integrated titanium family of interbody devices that are designed to […]
Abbott pulls Xience Alpine drug-eluting stent from Indian market
Abbott (NYSE:ABT) reportedly stopped selling its Xience Alpine drug-eluting coronary stent in India this week in response to price caps set by the National Pharmaceutical Pricing Authority. A spokesperson for the healthcare firm said in a statement that Abbott “fulfilled all the requirements to discontinue selling its Xience Alpine drug-eluting stent in India as of April […]
How these Boston Marathon runners kept their diabetes in check with Abbott’s FreeStyle Libre monitor
When Courtney Duckworth was first diagnosed with Type I diabetes, her glucometer was the size of a cell phone and she pricked her fingers nearly 12 times each day to keep track of her blood sugar. “I couldn’t feel the things that I touched because I had so many scabs,” she told Drug Delivery Business News. […]
Bigfoot brings Series B total to $55m with new investment from Abbott
Reeling in an $18 million add-on to the $37 million Series B that it reported last year, Bigfoot Biomedical touted today that it has raised over $90 million in total funding since the Milpitas, Calif.-based company first launched. Investments from Abbott (NYSE:ABT), which has an established partnership with Bigfoot, and other new and existing investors, brought the […]
MIT study reveals the problem with bioresorbable stents
Bioresorbable coronary scaffolds, designed to avoid the risks associated with the long-term implantation of metal stents, once captured the attention of medtech giants like Abbott (NYSE:ABT) and Boston Scientific (NYSE:BSX). But companies have since linked the use of these biodegradable polymer-based devices to a heightened risk of myocardial infarction and thrombosis, prompting Abbott to pull its Absorb […]
Judge rips into Abbott’s diabetes test strip supplier over discovery fraud
A supplier that sells an international version of Abbott‘s (NYSE:ABT) FreeStyle Diabetes test strips committed discovery fraud when it forked over only a select group of relevant documents last year, according to a U.S. magistrate judge. Lois Bloom ruled that the supplier, H&H, lost the right to invoke attorney-client privilege when it is deposed about […]